Grifols SA
NASDAQ:GRFS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Grifols SA (GRFS) under the Base Case is USD per share.
Compared with the current market price of 8.655 USD, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Grifols Does
Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines.
- Headquarters
- Spain ES
- Employees
- 25 000
- IPO date
- May 17, 2006
Grifols has no economic moat
Grifols SA lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Grifols SA
Earnings Waterfall
Grifols SA
What is the Intrinsic Value of one GRFS stock?
The intrinsic value for Grifols SA (GRFS) under the Base Case is USD.
Is GRFS stock undervalued or overvalued?
Compared with the current market price of 8.655 USD, the stock appears .
